Skip to main content
Clinical Trials/NCT02801253
NCT02801253
Recruiting
N/A

Prospective Cohort of Patients With Prosthetic Joint Infection

Groupe Hospitalier Diaconesses Croix Saint-Simon1 site in 1 country800 target enrollmentSeptember 11, 2015

Overview

Phase
N/A
Intervention
Not specified
Conditions
Prosthetic Joint Infection
Sponsor
Groupe Hospitalier Diaconesses Croix Saint-Simon
Enrollment
800
Locations
1
Primary Endpoint
Number of patients with hip and knee prosthetic joint reinfection (relapse and new infection) and multi-variable analysis of reinfection risk factors
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

Management of prosthetic joint infections (PJI) is a challenging task. These infections include different clinical and microbiological settings calling upon various treatment strategies according to infection type (acute or chronic), bone quality, the involved micro-organism and the patient's general condition and willing.

Treatment of PJI combines surgery and prolonged antibiotic therapy. In some patients with a high operative risk prolonged suppressive antibiotic therapy can be used.

Lack of large prospective studies motivated the conception of this cohort with a long term follow up, regardless to PJI management procedures.

Detailed Description

Large prospective cohort study in a French referral center for bone and joint infections. Population * all patients who consented to participate in the study with PJI treated with: * debridement-synovectomy for acute infection * with one-stage, two-stage exchange arthroplasty for chronic infection * other procedures (complete removal of the prosthesis) and antibiotic therapy * patients (non-operated or operated) receiving prolonged suppressive antibiotic therapy Outcome: * Follow-up at least 2 years * Events monitored: reinfection including relapse and new infection, joint revision for mechanical failure, PJI related or non-related death Study duration: 10 years. Recruitment period: 4 years. Maximal duration of data collection: 6 years. Investigator center: monocenter study. Mean patient inclusion per year: 100 patients per year.

Registry
clinicaltrials.gov
Start Date
September 11, 2015
End Date
September 2029
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Groupe Hospitalier Diaconesses Croix Saint-Simon
Responsible Party
Principal Investigator
Principal Investigator

Dr Valerie ZELLER

infectious diseases specialist

Groupe Hospitalier Diaconesses Croix Saint-Simon

Eligibility Criteria

Inclusion Criteria

  • Patient aged over 18 years old with hip, knee and or shoulder joint prosthesis who consented to participate in the study with:
  • According to musculoskeletal infection society definition: PJI is present when one of the major criteria exists or four out of six minor criteria.
  • Major Criteria:
  • Two positive periprosthetic cultures with phenotypically identical organisms, OR
  • A sinus tract communicating with the joint, OR
  • Minor Criteria:
  • Elevated serum C-reactive protein (CRP) AND erythrocyte sedimentation rate (ESR)
  • Elevated synovial fluid white blood cell (WBC)
  • Elevated synovial fluid polymorphonuclear neutrophil percentage (PMN%)
  • The presence of pus in the joint without known cause

Exclusion Criteria

  • Patient who does not meet eligibility criteria.
  • Patient lawfully deprived of his liberty.
  • Patient not insured under social security scheme.

Outcomes

Primary Outcomes

Number of patients with hip and knee prosthetic joint reinfection (relapse and new infection) and multi-variable analysis of reinfection risk factors

Time Frame: 2 years

Secondary Outcomes

  • Assessment of treatment failure rate in patients with hip and knee PJI 2 years after prolonged suppressive antibiotic therapy in non-operated patients.(2 years)
  • Assessment of reinfection rate of shoulder PJI two years after prosthesis revision with one or two stage exchange arthroplasty.(2 years)
  • Assessment of joint function at one, two, four and 6 years after prosthesis revision with one or two stage exchange arthroplasty.(1, 2, 4, 6 years)
  • Assessment of mechanical failure rate six years after prosthesis revision with one or two stage exchange arthroplasty(6 years)

Study Sites (1)

Loading locations...

Similar Trials